Clinical Trial

Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation

Study acronym: AZALEA-TIMI 71
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of the ANT-006 study is to evaluate the bleeding profile of abelacimab relative to rivaroxaban in patients with atrial fibrillation (AF) at moderate-to-high risk of stroke.
Protocol Amendment History 36 amendments
This ClinicalTrials.gov record has been amended 36 times since 2021-02-11; most recent amendment 2025-11-04.
Status change: Recruiting → Active, Not Recruiting 2021-12-14
Trial Details
NCT Number NCT04755283
Lead Sponsor Anthos Therapeutics, Inc.
Collaborators: Novartis Pharmaceuticals
Conditions Atrial Fibrillation (AF), Stroke
Enrollment 1,287 participants
Start Date 2021-02-02
Primary Completion 2024-02-15 (estimated)
Study Completion 2028-12-29 (estimated)
Updated on ClinicalTrials.gov 2025-11-06